Dolby Laboratories, Inc.(DLB)Earnings, Financials & Key Ratios

DLB•NYSE

$52.59

20.1× P/E·Price updated Jul 2, 2026

SectorTechnology IndustryIT Services Sub-IndustryVertical Software and Industry Platforms

AboutDolby Laboratories, Inc. creates audio and imaging technologies that transform entertainment and communications at the cinema, DTV, transmissions and devices, mobile devices, OTT video and music services, and home entertainment devices. The company develops and licenses its audio technologies, such as AAC & HE-AAC, a digital audio codec solution used for a range of media applications.; AVC, a digital video codec with high bandwidth efficiency used in various media devices; Dolby AC-4, an digital audio coding technology that delivers new audio experiences to a range of playback devices; and Dolby Atmos technology for cinema and a range of media devices. Its audio technologies also include Dolby Digital, a digital audio coding technology that provides multichannel sound to applications; Dolby Digital Plus, a digital audio coding technology that offers audio transmission for a range of media applications and devices; Dolby TrueHD, a digital audio coding technology providing encoding for media application; Dolby Vision, an imaging technology for cinema and media devices; Dolby Voice, an audio conferencing technology; and HEVC, a digital video codec with high bandwidth efficiency to support for media devices. In addition, the company designs and manufactures digital cinema servers, cinema processors, amplifiers, loudspeakers, hardware components, video conferencing solutions, and other products for the cinema, television, broadcast, communication, and entertainment industries. Further, it offers various services to support theatrical and television production for cinema exhibition, broadcast, and home entertainment. The company serves film studios, content creators, post-production facilities, cinema operators, broadcasters, and video game designers. It sells its products directly to the end users, as well as through dealers and distributors worldwide. Dolby Laboratories, Inc. was founded in 1965 and is headquartered in San Francisco, California.Show more

Revenue$1.35B+5.9%
EBITDA$364M+3.3%
Net Income$255M-2.6%
EPS (Diluted)2.62-2.6%
Gross Margin88.13%-0.9%
EBITDA Margin26.95%-2.5%
Operating Margin19.64%-5.5%
Net Margin18.9%-8.0%
ROE9.96%-7.5%

DLB Price & Volume

Dolby Laboratories, Inc. (DLB) stock price & volume — 10-year historical chart

Loading chart...

Licensing Dominance Faces Cyclical Revenue Growth Headwinds

Investment Thesis • Updated 2026Q2

VerdictNeutral

Growth:Mixed

Profitability:Strong

Financial:Fortress

Cash Flow:Mixed

Primary Risk:Royalty-free codec adoption

Key Thesis Takeaways

Dolby Laboratories maintains a fortress balance sheet with a negligible debt-to-equity ratio of 0.02, providing significant flexibility to navigate the inherent volatility of its consumer electronics licensing business.
While the company sustains high-margin operations with gross margins consistently near 88%, investors should monitor the long-term competitive threat posed by royalty-free codec adoption.
Future performance remains tethered to the timing of royalty recognitions and the company's ability to offset inconsistent revenue growth, which fluctuated between a 2.9% contraction and a 7.1% expansion in recent quarters.

Verdict Logic

while the company maintains a strong balance sheet and high gross margins of 88.7%, the inconsistent revenue growth and the long-term risk of royalty-free codec adoption warrant a cautious approach at a forward P/E of 12.41.

DLB Growth Metrics

Dolby Laboratories, Inc. (DLB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years3.35%

5 Years3.04%

3 Years2.47%

TTM3.39%

Profit CAGR

10 Years3.47%

5 Years1.97%

3 Years11.48%

TTM-5.06%

EPS CAGR

10 Years4.24%

5 Years3.09%

3 Years13.12%

TTM-4.53%

Return on Capital

10 Years10.18%

5 Years10.18%

3 Years10.06%

Last Year9.63%

DLB Recent Earnings

Dolby Laboratories, Inc. (DLB) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 12/12 qtrs (100%)●Beat Revenue 9/12 qtrs (75%)

Q2 2026Latest

Apr 30, 2026

Metric

Actual

Est

EPS

$1.37+4.6%

$1.31

Rev

$396M+2.5%

$386M

Q1 2026

Jan 29, 2026

Metric

Actual

Est

EPS

$1.06+6.7%

$0.99

Rev

$347M+1.6%

$341M

Q4 2025

Nov 18, 2025

Metric

Actual

Est

EPS

$0.99+41.6%

$0.70

Rev

$307M+0.4%

$306M

Q3 2025

Jul 31, 2025

Metric

Actual

Est

EPS

$0.78+9.2%

$0.71

Rev

$316M+3.2%

$306M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 30, 2026	$1.37vs $1.31+4.6%	$396Mvs $386M+2.5%
Q1 2026	Jan 29, 2026	$1.06vs $0.99+6.7%	$347Mvs $341M+1.6%
Q4 2025	Nov 18, 2025	$0.99vs $0.70+41.6%	$307Mvs $306M+0.4%
Q3 2025	Jul 31, 2025	$0.78vs $0.71+9.2%	$316Mvs $306M+3.2%

Based on last 12 quarters of dataView full earnings history →

Latest DLB News

Recent stock market news and headlines for Dolby Laboratories, Inc. (DLB)

Seeking Alpha·Jun 26, 2026

Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain

Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FDA's feedback gave their planned pivotal program a clearer path. Basically, DLB psychosis has no approved therapy, and zervimesine is a promising oral once-daily drug that already has interesting Phase 2 data. CGTX's SHIMMER trial was a good start, but their next trial must confirm longer-lasting hallucination and delusion benefits.

GlobeNewsWire·Jun 24, 2026

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

- Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease - - Company Developing NPI as a Measure of DLB Psychosis -

Peers Comparison

Key metrics vs top competitors for Dolby Laboratories, Inc. (DLB)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
DLBDolby Laboratories, Inc.Current	$52.59	$5.03B	20.07	5.92%	18.9%	9.96%	2.47%
IRDMIridium Communications Inc.	$55.72	$5.89B	52.57	4.93%	12.05%	22.76%	—
IPGPIPG Photonics Corporation	$114.41	$4.86B	156.73	2.73%	2.78%	1.37%	—
QCOMQUALCOMM Incorporated	$181.98	$191.81B	36.32	13.66%	22.31%	40.19%	—
IDCCInterDigital, Inc.	$282.26	$7.27B	23.92	-3.97%	44.2%	33.37%	—
VIAVia Transportation, Inc.	$18.96	$1.47B	-15.80	28.64%	-21.63%	-48.82%	—

Compare DLB vs Peers

Dolby Laboratories, Inc. (DLB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs IRDM

Most directly comparable listed peer for DLB.

Scale Benchmark

vs NVDA

Larger-name benchmark to compare DLB against a more recognizable public peer.

Peer Set

Compare Top 5

vs IRDM, IPGP, QCOM, IDCC

DLB SEC Filings & Documents

Dolby Laboratories, Inc. (DLB) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 30, 2026·SEC

Material company update

Feb 6, 2026·SEC

Material company update

Jan 29, 2026·SEC

10-K Annual Reports

FY 2025

Nov 18, 2025·SEC

FY 2024

Nov 19, 2024·SEC

FY 2023

Nov 17, 2023·SEC

10-Q Quarterly Reports

FY 2026

Apr 30, 2026·SEC

FY 2026

Jan 29, 2026·SEC

FY 2025

Jul 31, 2025·SEC

Get notified when DLB posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

DLB Frequently Asked Questions

Dolby Laboratories, Inc. (DLB) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Dolby Laboratories, Inc.'s revenue?

Dolby Laboratories, Inc. (DLB) reported $1.36B in revenue for fiscal year 2025. This represents a 528% increase from $217.5M in 2003.

How fast is Dolby Laboratories, Inc. growing?

Dolby Laboratories, Inc. (DLB) grew revenue by 5.9% over the past year. This is steady growth.

Is DLB profitable?

Yes, Dolby Laboratories, Inc. (DLB) is profitable, generating $243.6M in net income for fiscal year 2025 (18.9% net margin).

Dividend & Returns

Does DLB pay dividends?

Yes, Dolby Laboratories, Inc. (DLB) pays a dividend with a yield of 2.47%. This makes it attractive for income-focused investors.

What is DLB's return on equity?

Dolby Laboratories, Inc. (DLB) has a return on equity (ROE) of 10.0%. This is below average, suggesting room for improvement.

What is Dolby Laboratories, Inc.'s free cash flow?

Dolby Laboratories, Inc. (DLB) generated $258.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in DLB back in 2003?

Total return calculator · dividends reinvested · 23+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

Apr 30, 2026

$1.37vs $1.31+4.6%

$396Mvs $386M+2.5%

Q1 2026

Jan 29, 2026

$1.06vs $0.99+6.7%

$347Mvs $341M+1.6%

Q4 2025

Nov 18, 2025

$0.99vs $0.70+41.6%

$307Mvs $306M+0.4%

Q3 2025

Jul 31, 2025

$0.78vs $0.71+9.2%

$316Mvs $306M+3.2%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

DLBDolby Laboratories, Inc.Current

$52.59

$5.03B

20.07

5.92%

18.9%

9.96%

2.47%

IRDMIridium Communications Inc.

$55.72

$5.89B

52.57

4.93%

12.05%

22.76%

—

IPGPIPG Photonics Corporation

$114.41

$4.86B

156.73

2.73%

2.78%

1.37%

—

QCOMQUALCOMM Incorporated

$181.98

$191.81B

36.32

13.66%

22.31%

40.19%

—

IDCCInterDigital, Inc.

$282.26

$7.27B

23.92

-3.97%

44.2%

33.37%

—

VIAVia Transportation, Inc.

$18.96

$1.47B

-15.80

28.64%

-21.63%

-48.82%

—